{"generic":"Omacetaxine Mepesuccinate","drugs":["Omacetaxine Mepesuccinate","Synribo"],"mono":{"0":{"id":"930301-s-0","title":"Generic Names","mono":"Omacetaxine Mepesuccinate"},"1":{"id":"930301-s-1","title":"Dosing and Indications","sub":[{"id":"930301-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Chronic myeloid leukemia, Chronic or accelerated phase with resistance to or intolerance of 2 or more tyrosine kinase inhibitors:<\/b> induction, 1.25 mg\/m(2) SUBQ twice daily for 14 consecutive days every 28 days until a hematologic response is achieved<\/li><li><b>Chronic myeloid leukemia, Chronic or accelerated phase with resistance to or intolerance of 2 or more tyrosine kinase inhibitors:<\/b> maintenance, 1.25 mg\/m(2) SUBQ twice daily for 7 consecutive days every 28 days as long as a clinical benefit is maintained<\/li><\/ul>"},{"id":"930301-s-1-5","title":"Pediatric Dosing","mono":"safety and effectiveness not established in pediatric patients "},{"id":"930301-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>neutropenia, grade 4:<\/b> delay next cycle until absolute neutrophil count is 1 x 10(9)\/L or greater and reduce number of dosing days for next cycle by 2 days<\/li><li><b>thrombocytopenia, grade 3:<\/b> delay next cycle until platelet count is 50 x 10(9)\/L or greater and reduce number of dosing days for next cycle by 2 days<\/li><\/ul>"},{"id":"930301-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Chronic myeloid leukemia, Chronic or accelerated phase with resistance to or intolerance of 2 or more tyrosine kinase inhibitors<br\/>"}]},"3":{"id":"930301-s-3","title":"Contraindications\/Warnings","sub":[{"id":"930301-s-3-9","title":"Contraindications","mono":"specific contraindications have not been determined <br\/>"},{"id":"930301-s-3-10","title":"Precautions","mono":"<ul><li>anemia, Grade 3 or 4 including fatalities, has been reported; monitoring recommended; if occurs, delaying next cycle and\/or reducing days of therapy may be necessary<\/li><li>diabetes mellitus, poorly controlled; avoid use<\/li><li>elderly (65 years of age or older); increased risk for hematologic toxicity<\/li><li>hemorrhage, cerebral (some fatal) and gastrointestinal (severe but non-fatal), has been reported; increased risk with severe thrombocytopenia; monitoring recommended<\/li><li>hyperglycemia, Grade 3 or 4, has been reported; monitoring recommended, particularly in patients with diabetes or risk factors<\/li><li>neutropenia, Grade 3 or 4 including fatalities, has been reported; increases risk for infection; monitoring recommended; delaying next cycle and\/or reducing days of therapy may be required<\/li><li>platelet count less than 50,000\/microliter; avoid concomitant anticoagulants, aspirin, and NSAIDs; increased bleeding risk<\/li><li>pregnancy should be avoided<\/li><li>thrombocytopenia, Grade 3 or 4 including fatalities, has been reported; increased risk for hemorrhage; monitoring recommended; delaying next cycle and\/or reducing days of therapy may be required<\/li><li>report suspected adverse reactions to the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"930301-s-3-11","title":"Pregnancy Category","mono":"D (FDA)<br\/>"},{"id":"930301-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"930301-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Endocrine metabolic:<\/b>Increased uric acid level, Grade 3 or 4 (56% to 57%)<\/li><li><b>Gastrointestinal:<\/b>Diarrhea (35% to 42%), Nausea (27% to 32%)<\/li><li><b>Hematologic:<\/b>Anemia, All grades (51% to 61%), Febrile neutropenia, All grades (10% to 20%), Neutropenia, All grades (20% to 50%), Thrombocytopenia, All grades (56% to 74%)<\/li><li><b>Other:<\/b>Fatigue (26% to 31%), Fever (24% to 29%), Infectious disease (46% to 56%), Infusion reaction (22% to 34%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Acute coronary syndrome (1% to less than 10%), Cardiac dysrhythmia (1% to less than 10%)<\/li><li><b>Gastrointestinal:<\/b>Gastrointestinal hemorrhage (1% to less than 10%)<\/li><li><b>Hematologic:<\/b>Anemia, Grade 3 or 4 (36%), Febrile neutropenia, Grade 3 or 4 (10% to 16%), Neutropenia, Grade 3 or 4 (18% to 45%), Pancytopenia (10%), Thrombocytopenia, Grade 3 or 4 (49% to 67%)<\/li><li><b>Neurologic:<\/b>Cerebral hemorrhage (1% to less than 10%), Seizure (1% to less than 10%)<\/li><\/ul>"},"6":{"id":"930301-s-6","title":"Drug Name Info","sub":{"0":{"id":"930301-s-6-17","title":"US Trade Names","mono":"Synribo<br\/>"},"3":{"id":"930301-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"930301-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"930301-s-7","title":"Mechanism Of Action","mono":"Although the exact mechanism of omacetaxine mepesuccinate has not been fully determined, it is a protein synthesis inhibitor with effect against chronic myelogenous leukemia independent of direct Bcr-Abl binding.<br\/>"},"8":{"id":"930301-s-8","title":"Pharmacokinetics","sub":[{"id":"930301-s-8-23","title":"Absorption","mono":"<ul><li>Tmax, SubQ: 30 minutes<\/li><li>Bioavailability, SubQ: unknown<\/li><\/ul>"},{"id":"930301-s-8-24","title":"Distribution","mono":"<ul><li>Protein binding: 50% or less<\/li><li>Vd: 141 L<\/li><\/ul>"},{"id":"930301-s-8-25","title":"Metabolism","mono":"<ul><li>Plasma: hydrolysis via plasma esterases<\/li><li>4'-DMHHT (major): activity unknown<\/li><\/ul>"},{"id":"930301-s-8-26","title":"Excretion","mono":"<ul><li>Renal: less than 15% unchanged<\/li><li>Total body clearance: 177.4 mL\/kg\/hr<\/li><\/ul>"},{"id":"930301-s-8-27","title":"Elimination Half Life","mono":"6 hours <br\/>"}]},"9":{"id":"930301-s-9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/><ul><li>use proper procedures for handling and disposal of chemotherapy<\/li><li>omacetaxine should be prepared in a healthcare facility by a healthcare professional; it may be administered at home in an appropriate candidate<\/li><\/ul><\/li><li><b>Subcutaneous<\/b><br\/><ul><li>reconstitute vial with 1 mL NS to yield a 3.5 mg\/mL solution<\/li><li>gently swirl to solubilize powder (less than 1 minute)<\/li><li>use immediately or within 12 hours if stored at room temperature; use within 6 days (144 hours) if refrigerated<\/li><\/ul><\/li><\/ul>"},"10":{"id":"930301-s-10","title":"Monitoring","mono":"<ul><li>cytogenic and\/or hematologic response indicate efficacy<\/li><li>CBC weekly at start of treatment and with initial maintenance cycles, then every 2 weeks or as clinically indicated; especially platelet count  and differential<\/li><li>blood glucose levels frequently, especially in patients at-risk for or with diabetes<\/li><\/ul>"},"11":{"id":"930301-s-11","title":"How Supplied","mono":"<b>Synribo<\/b><br\/>Subcutaneous Powder for Solution: 3.5 MG<br\/>"},"13":{"id":"930301-s-13","title":"Clinical Teaching","mono":"<ul><li>Warn female patients of childbearing potential to avoid pregnancy as drug may cause fetal harm.<\/li><li>Instruct patient to report any upcoming dental or surgical procedures.<\/li><li>Advise nursing women to discontinue breastfeeding while receiving drug.<\/li><li>Patient should avoid activities requiring mental alertness or coordination until drug effects are realized as drug may cause fatigue.<\/li><li>Side effects may include fatigue, fever, asthenia, headache, diarrhea, nausea, and alopecia.<\/li><li>Tell patient to report redness, swelling, or pain at injection site<\/li><li>Instruct patient to report symptoms of bleeding (eg, unusual bleeding, easy bruising) or myelosuppression (eg, fever, shortness of breath, fatigue).<\/li><li>Advise patient that this drug may cause glucose intolerance and hyperglycemia.<\/li><li>If home administration is required, train patient on proper handling, storage, administration, and disposal.<\/li><li>If a dose is missed, skip the missed dose and continue with the normal dosing schedule.<\/li><\/ul>"}}}